The risk of severe COVID-19 complications and death for patients receiving bispecific antibody therapy has significantly decreased due to advancements in:
Antiviral prophylaxis: Effective antiviral medications can now be used preventatively to significantly reduce the chances of developing severe COVID-19 infection.
Immunoglobulin replacement therapy (IVIG): For patients with low immunoglobulin levels, intravenous immunoglobulin infusions can further strengthen their immune system and help them fight infections, including COVID-19.
The COVID-19 vaccine (typically all myeloma patients receive this vaccination).
COVID-19 and bispecific antibody therapy